Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

INCA033989: the first shot on goal for MPNs?

Benlabiod C. and Psaila B., (2024), Blood, 144, 2278 - 2279

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

O'Sullivan J. et al, (2024), British Journal of Haematology

A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.

Li R. et al, (2024), Sci Transl Med, 16

The fetal specific geneLIN28Bis essential for human fetal B-lymphopoiesis and initiation of KMT2A::AFF1 infant leukemia

Ling R. et al, (2024)

Generating human bone marrow organoids for disease modeling and drug discovery.

Olijnik A-A. et al, (2024), Nat Protoc

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A.

Brierley CK. et al, (2023), bioRxiv

The management of myelofibrosis: A British Society for Haematology Guideline.

McLornan DP. et al, (2023), Br J Haematol

Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib.

Rampotas A. et al, (2023), Blood

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.

McLornan DP. et al, (2023), Br J Haematol

Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.

Rodriguez-Meira A. et al, (2023), Nat Genet, 55, 1531 - 1541

Data from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Data from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 1 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 1 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 2 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 2 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 3 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 3 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 4 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 4 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Load More